<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389478</url>
  </required_header>
  <id_info>
    <org_study_id>FNF201421</org_study_id>
    <nct_id>NCT02389478</nct_id>
  </id_info>
  <brief_title>Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants</brief_title>
  <official_title>Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants：Effects on Secretory Immunoglobulin A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effects of Oropharyngeal administration of&#xD;
      colostrum to very low birth weight infants on sIgA and lactoferrin, in order to explore the&#xD;
      protect immune function of colostrum to very low birth weight infants, to improve the&#xD;
      utilization of breast milk and reduce infection rates of very low birth weight infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of very low born weight infants increased every year.they are suffer from many&#xD;
      questions.Recent studies have shown that Oropharyngeal administration of colostrum to very&#xD;
      low birth weight infants can reduce the time reach full enteral nutrition .But there are no&#xD;
      evidence support that it can promote infants' immune response. The hypothesis of the current&#xD;
      study is that Oropharyngeal administration of colostrum to very low birth weight infants may&#xD;
      increase the secretion of sIgA in urine and saliva.&#xD;
&#xD;
      The current study adopts randomized, double blind, controlled intervention trial, gives&#xD;
      Oropharyngeal administration of colostrums to very low birth weight infants in intervention&#xD;
      group and Oropharyngeal administration of Normal saline to control group. All indicators in&#xD;
      this study are discrete traits, for sIgA、Lactoferrin number in Saliva and urine， number of&#xD;
      CRP，time Begin oral feeding，time up to full enteral feeding， Person's chi-square tests were&#xD;
      used for comparisons. For Blood culture results，The number of necrotizing enterocolitis (NEC)&#xD;
      occurred， the investigators use Chi-square tests for comparisons between two groups. The&#xD;
      study expects that Oropharyngeal administration of colostrum to very low birth weight infants&#xD;
      can increase the secretion of sIgA in urine and saliva.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in sIgA at 7 days</measure>
    <time_frame>at baseline（first time baby in hospital） and at 7 days</time_frame>
    <description>in urine and saliva</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in lactoferrin at 7 days</measure>
    <time_frame>at baseline（first time baby in hospital） and at 7 days</time_frame>
    <description>in urine and saliva</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in sIgA at 21 days</measure>
    <time_frame>at baseline（first time baby in hospital） and at 21 days</time_frame>
    <description>in urine and saliva</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in lactoferrin at 21 days</measure>
    <time_frame>at baseline（first time baby in hospital） and at 21 days</time_frame>
    <description>in urine and saliva</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration from admission to the start of oral feeding</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 days</time_frame>
    <description>when the first time participants start bottle feeding by mouth（&gt;5ml/once）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration from the start of enteric feeding to full enteric feeding</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 14 days</time_frame>
    <description>when the volume of milk participants take by mouth up to 140ml/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with necrotizing enterocolitis (NEC)</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Infant, Very Low Birth Weight</condition>
  <arm_group>
    <arm_group_label>colostrums</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oropharyngeal administration of colostrums, every 4 hours，continue for 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oropharyngeal administration of colostrums</intervention_name>
    <description>rubbing drops of colostrum inside a baby's cheeks using a sterile syringe</description>
    <arm_group_label>colostrums</arm_group_label>
    <other_name>oral immune therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oropharyngeal administration of Normal saline</intervention_name>
    <description>rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Born weight≤1500g&#xD;
&#xD;
          2. transferred to our hospital within 24 hours after birth&#xD;
&#xD;
          3. the mother can provide colostrum&#xD;
&#xD;
          4. parents of the infants agreed to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The infants suffering from life-threatening conditions ,such as severe heart&#xD;
             disease,whose survival time are expected &lt;30d&#xD;
&#xD;
          2. The infants suffering from any kinds of disease,which impact they take human milk by&#xD;
             mouth.(such as gastrointestinal malformations, NEC, etc.）&#xD;
&#xD;
          3. human milk is contraindicated&#xD;
&#xD;
               -  An infant whose mother :&#xD;
&#xD;
                    -  Is infected with the human immunodeficiency virus (HIV)&#xD;
&#xD;
                    -  Is taking antiretroviral medications&#xD;
&#xD;
                    -  Has untreated active tuberculosis&#xD;
&#xD;
                    -  Is infected with human T-cell lymphotropic virus type l or ll&#xD;
&#xD;
                    -  Is using or dependent on an illicit drug except if the breastmilk is&#xD;
                       medically indicated&#xD;
&#xD;
                    -  Is taking prescribed cancer chemotherapy agents contraindicated for&#xD;
                       breastfeeding&#xD;
&#xD;
                    -  Is receiving any medications contraindicated in breast feeding&#xD;
&#xD;
                    -  Is receiving diagnostic or therapeutic radioactive isotopes or exposure to&#xD;
                       radioactive materials (for as long as they are radioactive in the milk)&#xD;
&#xD;
               -  An infant diagnosed with galactosemia, a rare genetic metabolic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang YuXia, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Children Hospital of Fudan University</affiliation>
  </overall_official>
  <reference>
    <citation>Rodriguez NA, Meier PP, Groer MW, Zeller JM. Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives. J Perinatol. 2009 Jan;29(1):1-7. doi: 10.1038/jp.2008.130. Epub 2008 Sep 4. Review.</citation>
    <PMID>18769379</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>February 8, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oropharyngeal</keyword>
  <keyword>breastmilk</keyword>
  <keyword>colostrum</keyword>
  <keyword>human milk</keyword>
  <keyword>premature infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

